CGH
CRSP icon

Contrarius Group Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Contrarius Group Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-156,605
Closed -$8.21M – 44
2025
Q4 		$8.21M Sell
156,605
-113,745
-42% -$6.81M 0.4% 35
2025
Q3 		$17.5M Sell
270,350
-104,604
-28% -$6.01M 0.79% 20
2025
Q2 		$18.2M Buy
374,954
+42,982
+13% +$1.66M 1.03% 17
2025
Q1 		$11.3M Sell
331,972
-36,839
-10% -$1.56M 0.77% 24
2024
Q4 		$14.5M Buy
+368,811
New +$17.4M 0.89% 23

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Contrarius Group Holdings's CRSP Position: Q1 2026 in Review

Contrarius Group Holdings sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 156,605 shares — an estimated $8.21M sold.

Contrarius Group Holdings first reported a position in CRSP in Q4 2024 and held it in 5 quarters. The position peaked at $18.2M in Q2 2025. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Contrarius Group Holdings reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Contrarius Group Holdings sold 156,605 CRISPR Therapeutics shares in Q1 2026, an estimated $8.21M.
  • Contrarius Group Holdings first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 5 quarters.
  • Contrarius Group Holdings's CRISPR Therapeutics position peaked at $18.2M in Q2 2025.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Contrarius Group Holdings's 13F filing for Q1 2026, filed 11 May 2026.